POPULARITY
20 episodes with HIF
154 episodes with HIF
9 episodes with HIF
6 episodes with HIF
4 episodes with HIF
7 episodes with HIF
6 episodes with HIF
5 episodes with HIF
2 episodes with HIF
3 episodes with HIF
3 episodes with HIF
3 episodes with HIF
3 episodes with HIF
8 episodes with HIF
3 episodes with HIF
3 episodes with HIF
2 episodes with HIF
2 episodes with HIF
2 episodes with HIF
3 episodes with HIF
38 episodes with HIF
3 episodes with HIF
2 episodes with HIF
3 episodes with HIF
3 episodes with HIF
24 episodes with HIF
2 episodes with HIF
21 episodes with HIF
2 episodes with HIF
3 episodes with HIF
3 episodes with HIF
2 episodes with HIF
17 episodes with HIF
16 episodes with HIF
2 episodes with HIF
13 episodes with HIF
12 episodes with HIF
2 episodes with HIF
2 episodes with HIF
6 episodes with HIF
6 episodes with HIF
4 episodes with HIF
4 episodes with HIF
3 episodes with HIF
3 episodes with HIF
Podden är tillbaka efter 3-0 mot HIF. Om inramningen, BoIS nyfunna lidande under matcher och firandet på stan efteråt. Men också en glimt framåt, hur länge stannar egentligen Edi i BoIS och vem ersätter Perez i tisdagens match? Kom ihåg att swisha tifogruppen för deras mäktiga arbete. Heja BoIS!
What if the reason your cells are breaking down isn't a mystery - it's simply a lack of oxygen? In this episode of Integrative Cancer Solutions, Dr. K sits down with Teresa Reile, cancer survivor, hypoxia specialist, and founder of Patriox Health Freedom, to share a story that goes far beyond a diagnosis. After surviving cervical cancer in 2012 while managing 48 companies and going through a divorce, Teresa discovered a decade later that the cancer had returned - silently. What she found in Hungary, a drinkable and bathable oxygen technology developed over 25 years, cleared her scan results in under three weeks. Now she's brought that technology to the United States. This conversation covers the real root cause most doctors never test for, why cellular hypoxia underlies nearly every chronic condition, how the HIF-1 alpha test can detect it before disease takes hold, and why oxygen may be the most overlooked nutrient in modern medicine. Key Takeaways: 0:00 Introduction 1:27 Running 48 companies, a divorce, and a cancer diagnosis 3:20 Getting the news and still making it to the wedding 5:08 What the medical system got wrong after surgery 10:28 When cancer came back a decade later 13:42 Cellular hypoxia and how it starts the disease process 28:23 Why cancer hates oxygen and what that means for treatment 37:30 Words of wisdom for high-achieving entrepreneurs Schedule a Free 15-Min Cancer/Lyme Consultation at The Karlfeldt Center: 208-338-8902 Resources: Patriox Health Freedom — https://patriox.us/ Medical Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or replace professional medical advice. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions. ____________________________________RESOURCES FROM DR. KARLFELDT:
ReferencesInt. J. Mol. Sci. 2023, 24(4), 3120Cell Death & Differentiation 2021. v28, pages 3357–3370Neuropsychiatr Dis Treat. 2025 Sep 10;21:2035–2052. JACCCardiovasc Interv.2025 Apr 28;18(8):963-971Guerra, DJ.2026. Unpublished LecturesBiber, HIF.. 1674. Passagalia C.105https://music.youtube.com/watch?v=MohWMCmO3SE&si=1BjlIDO7HuI_GxaM Jagger/Richards. 1970 Wild Horses Rolling Stoneshttps://open.spotify.com/track/4M4Q3JLsUbyTkd5WHty1WB?si=81cc8e5c47d74958
Jodå, det dras allt en lans för domaren efter tisdagens förlust mot HIF. Och – har Rikard Norling fått order om att spela de yngre spelarna?
Anemia in chronic kidney disease remains common, complex, and rapidly evolving. In this episode, experts discuss key updates from the 2026 KDIGO Clinical Practice Guidelines and AJKD commentary, including a stronger focus on identifying and treating iron deficiency and refining treatment strategies. The conversation explores the clinical impact of anemia on cardiovascular risk and quality of life, reviews evidence supporting proactive IV iron use, and examines emerging therapies such as HIF stabilizers. The panel also addresses real world challenges in managing anemia, particularly in non dialysis CKD populations, where access, adherence, and care coordination play a critical role. This episode provides practical insights to support individualized, evidence based anemia care. Please click here to access the commentary.
Avsnitt 514 av Sveriges nyfiknaste podd gästas av Andreas Granqvist. Trelleborgs FF:s nye manager talar om varför han valde division-1-klubben, om målet att ta tillbaka TFF till elitfotbollen, om telefonsamtalet till miljardären som gav ett träningsläger, om vilka tränare som inspirerar honom, om vilket ledarskap han vill stå för, om tränarna vars metoder snarare skrämt, om fotbollen han vill spela, om den höga målsättningen som tränare och om drömmen att bli förbundskapten en gång i framtiden.Dessutom berättar Granqvist om den tuffa skilsmässan från HIF, om första besöket på Olympia sedan han fick sparken, om tron på klubbens vägval nu, om att skånsk herrfotboll underpresterar, om att svensk fotboll gått i från vad man varit, om att “Granen” inte hade kunnat spela JDT:s försvarsspel, om förklaringen till Potters VM-framgång och om vad som måste sitta för att Sverige ska lyckas i VM. Hosted on Acast. See acast.com/privacy for more information.
At the 3rd Biennial Miami Precision Medicine Conference, CancerNetwork® spoke with a variety of researchers and clinicians who presented on different topics regarding the use of targeted therapies across several cancer types. Faculty from the University of Miami Sylvester Comprehensive Cancer Center shared key advances and ongoing initiatives across pancreatic cancer, sarcomas, genitourinary malignancies, and other diseases.First, Jashodeep Datta, MD, an associate professor of surgery, a co-leader of the Gastrointestinal Site Disease Group, an associate director of Translational Research, and Sylvester Pancreatic Cancer Research Institute DiMare Family Endowed Chair in Immunotherapy, discussed his presentation on overcoming a historical “moratorium” associated with immunotherapy in pancreatic cancer. Based on recent data, he noted that current goals include analyzing distinct subpopulations of patients who respond to immunotherapy and understanding the biology of why they respond to inform the design of novel therapeutic approaches. Looking towards the future, Datta described how mRNA vaccines may play a larger role in advancing personalized patient care.Next, Steven Bialick, DO, a gastrointestinal and sarcoma and connective tissue medical oncologist, spoke about his presentation on diagnosing and treating patients with sarcomas. He highlighted how markers like microsatellite instability-high status may help identify patients who are suitable candidates to receive immunotherapies like pembrolizumab (Keytruda). Overall, he emphasized the practice of thorough molecular testing to help navigate a treatment landscape that has “changed so dramatically” over the years. Finally, Jaime Merchan, MD, director of the Phase 1 Program and a tenured professor of medicine at the University of Miami Miller School of Medicine, talked about his presentation on the development of novel targeted therapies in genitourinary malignancies, which included bladder and kidney cancers. He described strategies for using new HIF-2⍺ inhibitors alongside therapeutic standards like tyrosine kinase inhibitors. Additionally, he detailed how other investigational drug classes, including oncolytic viruses and T-cell engagers, may fit into the treatment paradigm for these genitourinary cancers. References Datta J. Mission impossible? Strategies for precision immunotherapy in pancreatic cancer. Presented at the 3rd Biennial Miami Precision Medicine Conference; April 11-12, 2026; Fort Lauderdale, FL. Bialick S. Precision oncology in the diagnosis and management of sarcoma patients. Presented at the 3rd Biennial Miami Precision Medicine Conference; April 11-12, 2026; Fort Lauderdale, FL. Merchan J. Genitourinary cancers: bladder and kidney. Presented at the 3rd Biennial Miami Precision Medicine Conference; April 11-12, 2026; Fort Lauderdale, FL.
In this episode, Dirk Singer speaks with Meg Gentle, Executive Director at HIF Global, about how synthetic fuels and waste-based pathways could reshape the economics of sustainable aviation fuel.Gentle discusses:Why Chile's exceptional wind resources made it the starting point for HIF's first e-fuels facility, and how that model is now being replicated globallyHow e-fuels are produced by combining green hydrogen with captured CO2 to create transportable liquid fuels like methanol and jet fuelWhy HIF Global is pursuing two SAF pathways in parallel: e-methanol-to-jet for Europe and RNG-based SAF for the USHow waste-based fuels, particularly those derived from methane emissions, can achieve very low or even negative carbon intensityWhy the real bottleneck to scaling SAF is not technology or capital, but long-term policy certainty and “early mover protection”How SAF markets could evolve toward a carbon intensity-based pricing model, where fuels compete on dollars per tonne of CO2 abated rather than feedstock or pathwayIf you LOVED this episode, you'll also love the conversation we had with James Hygate, CEO of Firefly Green Fuels, who discusses the company's novel approach that turns sewage into jet fuel. Check it out here. Learn more about the innovators who are navigating the industry's challenges to make sustainable aviation a reality, in our new book ‘Sustainability in the Air: Volume 2'. Click here to learn more.Feel free to reach out via email to podcast@simpliflying.com. For more content on sustainable aviation, visit our website green.simpliflying.com and join the movement. It's about time.Links & More:HIF GlobalHIF Haru Oni: The first operating e-Fuels facility in the world - HIF Global HIF Global and eFuel One ink deal for gigawatt-scale green hydrogen and methanol project in Uruguay - Fuel Cells Works HIF Global to provide green hydrogen-based fuels for tourists in southern Chile and Antarctica this summer - Hydrogen Insight
Entrevista Central - ¿Qué implicaría una planta HIF en Paysandú, según la visita al piloto en Chile? by En Perspectiva
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium, noting presentations to watch at sessions on prostate cancer, bladder cancer, and renal cell carcinoma (RCC).For prostate cancer, the experts revealed that they're looking forward to seeing updated results from the phase 3 PEACE-3 trial (NCT02194842) of enzalutamide (Xtandi) plus radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), noting that bone-protecting agents are mandatory for patients receiving radium-223. They also pointed to overall survival data from the phase 2 BRCAAway trial (NCT03012321) of abiraterone (Zytiga) plus prednisone and olaparib (Lynparza) for patients with mCRPC harboring BRCA or ATM alterations. Additionally, they spotlighted the phase 3 PEACE 2 trial (NCT01952223), which explores moving chemotherapy into the localized prostate cancer setting.Regarding bladder cancer, they identified the phase 3 KEYNOTE-B15 trial (NCT04700124) as a potentially practice-changing trial evaluating perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in cisplatin-eligible patients with muscle-invasive bladder cancer. They also noted that circulating tumor DNA data are a significant trend, appearing in several clinical trials to guide response-adapted management.For RCC, the hosts highlighted the phase 3 LITESPARK-011 (NCT04586231) and LITESPARK-022 (NCT05239728) trials, which are evaluating the HIF-2α inhibitor belzutifan (Welireg) in different RCC populations. They also emphasized the importance of the CLIMATE study (ACTRN12622000247774) for detecting residual disease in patients with testicular cancer.
This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies.Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immunotherapy is not a one-time opportunity. We also highlight both the BNT111 RNA-based lipoplex immunotherapy targeting agent and the question of whether early discontinuation of immunotherapy could be beneficial.Studies:LITESPARK-15IMPRESS-Norway trialAbstract 1510M0BNT111 (NCT04526899)Safe Stop TrialFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases. We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following disease progression, the importance of understanding disease biology, and the nuances of NCCN guidelines. Key topics included: • The role of TKI options like Axitinib, Cabozantinib, and Tivozanib in second-line treatment • The impact of disease progression on treatment decisions • Side effect management and the importance of palliative care • The potential use of HIF-2 alpha inhibitors like Belzutifan in specific scenarios Join us for an informative discussion that emphasized patient-centered care and the significance of shared decision-making in oncology. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ If you enjoy our conversations, please leave us a review and let us know what topics you'd like us to cover in future episodes! Stay tuned for more insights into the rapidly evolving field of cancer treatment. We are the Oncology Brothers! #RCC #KidneyCancer #TKI #Immunotherapy #OncologyBrothers #GUOncology
La Mesa - Jueves 27.11.2025 - Lubetkin recibió a su par de Argentina para analizar impactos de HIF by En Perspectiva
The supplement certification landscape is evolving, and Episode #193 of the PricePlow Podcast brings you to the forefront of this transformation. We sit down with Lori Bestervelt, Ph.D., and Thane Campbell from TruShieldâ„¢ Certified, a new certification service that’s challenging the status quo by focusing exclusively on comprehensive banned substance testing. With Lori’s 22 years creating industry standards at NSF International (including the foundational NSF 173 standard) and Thane’s expertise from SMRTL (one of only two WADA-experienced anti-doping laboratories in the United States), they’re introducing a certification approach that tests for well over 400 prohibited substances, including entire drug classes like glucocorticoids and HIF stabilizers that other programs overlook. TruShieldâ„¢ Certified: Finished Product Drug-Testing from an Elite Lab Unlike traditional bundled certification programs that require brands to repeat testing across multiple areas they may already have covered, TruShield takes a streamlined approach by focusing solely on what athletes and tested individuals need most: certainty that their supplements are free from banned substances. The conversation explores the evolution of performance-enhancing substances from prohormones to SARMs to peptides, the challenges of cross-contamination in manufacturing, and why the certification industry hasn’t kept pace with modern supply chain realities. Whether you’re a brand looking to protect athletes or a consumer wanting transparency about what’s in your supplements, this episode delivers critical insights into the future of supplement safety. Subscribe to the PricePlow Podcast on your favorite platform and sign up for TruShield Certified news alerts on PricePlow before we dive into the details! https://blog.priceplow.com/podcast/trushield-certified-193 Video: Introducing TruShieldâ„¢ Certified with Lori Bestervelt and Thane Campbell https://www.youtube.com/watch?v=G-m-QHg6nDk Detailed Show Notes: TruShieldâ„¢ Certified’s Approach to Banned Substance Testing (0:00) – Introductions and Background (3:00) – The Problem with Bundled Certification Services (5:00) – Industry Evolution and Current Gaps (7:00) – Thane’s Background and SMRTL’s Role (9:00) – The Evolution of Banned Substances (11:00) – Consumer Safety and Informed Decisions (15:00) – Testing Methodology and Laboratory Capabilities (20:30) – The Lot-by-Lot Certification Process (25:45) – Cross-Contamination Challenges in Manufacturing (32:15) – Cost Considerations and Accessibility (35:30) – Early Adopters: CON-CRÄ’T, RedLeaf Biologics, and Vireo (40:45) – International Expansion and Geographic Availability (47:15) – League Endorsements and Adoption (53:00) – The Competitive Landscape (58:45) – Manufacturing Partnerships and Supply Chain Transparency (1:04:30) – Future Trends and Emerging Substances (1:09:15) – The Caffeine Question and WADA Regulations (1:13:45) – Partnership with Eurofins and Closing Thoughts Where to Follow Lori B… Read more on the PricePlow Blog
Avsnitt 491 av Sveriges nyfiknaste podd gästas av Klebér Saarenpää. Helsingborgs tränare talar om en säsong som inte blivit som tänkt, om att laget överpresterade 2024 när man kom fyra, om nyförvärv som inte funkat, om försäljningarna som påverkade lagets kvalitet, om avgångskraven från supportrarna, om de höga förväntningarna som följer i Helsingborg, om stödet från HIF-ledningen som förlängt hans kontrakt och om tron på att 2026 blir bättre när man förhoppningsvis kan satsa mer.Dessutom berättar Saarenpää om genombrottet som mittback, om intresset från Bundesliga och Serie A, om när han hjälpte Sverige till VM 2002 men även om de svåra skadorna som gjorde honom deprimerad, om att slutade för att plugga i stället, om kampen för att trots det komma tillbaka på elitnivå, om varför han satsade på en tränarkarriär, om förebilderna som tränare, om sparken i danska Vejle, om när han var nära att ta upp Brage i Allsvenskan och om drömmen att nå högsta nivå som tränare. Hosted on Acast. See acast.com/privacy for more information.
On this week's episode, Tess Cameron, Brian Skorney, Sam Fazeli, Yaron Werber, and Luba Greenwood, kick off with a pop quiz on the last time the $XBI hit 105 (spoiler, it was 2021) driven by recent positive news. The co-hosts highlight a steady rate of M&A activity, including Novo Nordisk's acquisition of Akero Therapeutics highlighting continued interest in metabolic conditions and BMS' acquisition of Orbital Therapeutics reflecting growing momentum around in vivo CAR-T delivery platforms. The LB Pharma and MapLight IPOs are also mentioned. The conversation shifts to AI pharma deals, spotlighting AstraZeneca's partnership with Algen Biotechnologies and Sanofi's collaboration with BenchSci, both designed to accelerate discovery and target identification. In other financing news, the co-hosts cover Nilo Therapeutics' $101 million Series A financing and the debut of Ascenta's $325 million biotech fund. In data news, the group covers Arcus' HIF-2a monotherapy data in kidney cancer, Dyne Therapeutics' encouraging results in DM1, and Ionis' pipeline and platform updates presented at its Innovation Day. The episode concludes with Lexeo Therapeutics' regulatory updates for its Freidreich's ataxis gene therapy and discussion on Peter Marks' transition from the head of CBER to Eli Lilly, noting the pharma-agency “revolving door.” *This episode aired on October 10, 2025.
Podden är tillbaka efter matcherna mot HIF och Utsikten. Om oförmågan att hitta kontinuitet, den återstående (intetsägande?) delen av säsongen och hur Asterhed bör ställa upp framöver. Men också ett större grepp om hur säsongen kunnat utvecklas på detta sätt, vem som bär ansvar och vilken påverkan det kan komma att ha kommande år. Heja BoIS!
Send us a textHow maternal obesity epigenetically reprograms liver metabolism in offspring, predisposing them to metabolic disease.Episode Summary: Dr. Elvira Mass talks about macrophages, specialized immune cells that vary by tissue and play crucial roles beyond fighting infections, such as supporting organ function; Kupffer cells (liver macrophages) and how maternal obesity during pregnancy reprograms these cells in offspring, leading to fatty liver disease, fibrosis, and even cancer later in life, based on mouse studies showing epigenetic and metabolic shifts like increased glycolysis, with insights into developmental windows, nutritional mismatches, and broader implications for human health.About the guest: Elvira Mass, PhD, is a Professor of Developmental Immunology at the University of Bonn in Germany, where her lab focuses on the development and function of macrophages in various tissues.Discussion Points:Macrophages are diverse, tissue-specific cells that develop from embryonic precursors, performing unique tasks like providing growth factors in organs.Kupffer cells in the liver monitor blood from the gut and are exposed to maternal nutrients during fetal development.Maternal obesity (induced in mice via high-fat diets) programs offspring Kupffer cells epigenetically, leading to fatty liver in newborns and progression to diseases like cancer, even on normal diets.A "nutritional mismatch" between in utero high-fat exposure and postnatal normal diets worsens liver issues, as cells are "prepared" for excess high-fat intake but face scarcity.Key mechanism: Reprogrammed Kupffer cells overproduce apolipoproteins, driving excess lipid uptake in liver cells (hepatocytes), linked to transcription factor HIF-1α and a shift to inefficient glycolysis.Offspring from obese mothers show sex differences (males affected earlier) and persistent changes.Human parallels: Rising childhood fatty liver (once rare and tied to alcoholism) correlates with maternal obesity; studies like Dutch Hunger Winter show early gestational disruptions cause lifelong issues.Broader factors: Microbiome changes, specific fatty acids, and environmental toxins like microplastics may also reprogram macrophages; diets in studies vary beyond fat content, affecting results.Advice: Maintain consistent healthy habits pre- and during pregnancy; avoid sudden diet shifts, as developmental windows are critical for long-lived cells like Kupffer cells.Reference Paper:Study: Kupffer cell programming bySupport the showAffiliates: Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. For all the ways you can support my efforts
In this episode, I open up about the two resources I created to help parents and educators take real action against bullying:
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC). Episode Highlights: • Understanding TKIs and HIF-2 Inhibitors: A discussion on the available oral treatment options for RCC, including cabozantinib, lenvatinib, and axitinib. • Dosing Strategies: Insights on starting doses, titration, and the importance of managing side effects without compromising quality of life. • Common Side Effects: hypertension, diarrhea, fatigue, and how they relate to the class effect of these medications. • Clinical Pearls: Dr. Pal shared valuable tips on managing toxicities, including the use of treatment breaks and supportive care strategies. • Second-Line Treatments: A look at tivozanib and belzutifan, including their unique side effects and management strategies. Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.
In this episode of BFR Radio, we explores a novel and practical approach to blood flow restriction (BFR) training—applying BFR after sprint intervals, during the recovery period. Drawing on recent research in trained cyclists, we examine how this method can significantly increase VO₂max (by 4.5%) without compromising sprint performance or technique. This episode goes beyond the data—highlighting why improving aerobic capacity matters, particularly for athletes in sprint-based or high-intensity intermittent sports. Enhancing oxygen delivery and mitochondrial density not only supports aerobic efficiency but also plays a key role in buffering capacity, lactate clearance, and recovery between high-output efforts. Key Points Discussed: Study overview: Sprint interval training with post-exercise BFR Increases in VO₂max without detriment to sprint performance Muscle biopsy findings: HIF-1α and its role in angiogenesis Why aerobic development is critical—even for sprinters Potential applications in track and field (200–400m), rugby sevens, and other high-intensity running sports Practical programming: Suggested BFR recovery protocol after sprint efforts Short- vs long-term adaptation: What to monitor beyond VO₂max This approach is particularly valuable when BFR during the work phase is not feasible or tolerable. By applying BFR during passive recovery, coaches and athletes may unlock meaningful adaptations without interfering with intensity or movement quality. Thanks for listening, and remember to keep the pump! Chris
Welcome to Art is Awesome, the show where we talk with an artist or art worker with a connection to the San Francisco Bay Area. In this Episode, Emily chats with "The Button Man", Harlem artist Beau McCall, an artist renowned for his unique use of buttons in wearable and visual art. McCall's work is featured in prominent collections such as New York's Museum of Arts and Design and London's Victoria and Albert Museum. McCall recounts his upbringing in Philadelphia, his move to Harlem, and his early inspirations. He explains how his fascination with buttons began with his mother's collection and grew through various craft classes. McCall shares memories of his artistic evolution, his experiences with the Harlem community, and the personal significance of his work, including tributes to friends lost to AIDS. The episode concludes with McCall's advice to aspiring artists and a nod to his ongoing support from his mother.About Artist Beau McCall :Drawing inspiration from the vast button collection of his mother and family, Beau McCall creates wearable and visual art by applying clothing buttons onto mostly upcycled fabrics, materials, and objects. With deliberate focus the buttons are arranged to stimulate one's curiosity and imagination, while simultaneously drawing attention to the unique history of buttons. Thereby McCall's work generates a discussion surrounding many topics such as pop culture and social justice.McCall began his professional career in Harlem in the 1980s after arriving from his native, Philadelphia with nothing more than a few hundred dollars, a duffel bag, and buttons. Circa 1988 he made his critically acclaimed wearable art debut at The Harlem Institute of Fashion (HIF) show for HARLEM WEEK. McCall went on to become an established force within HIF's Black Fashion Museum collective presenting at their shows consecutively through circa 1995, as well being featured in their museum exhibitions and prestigious events. During this time, McCall's visually captivating work was featured in the fashion bible Women's Wear Daily, on the PBS version of George C. Wolfe's The Colored Museum (1991), and in the award-winning film Quartier Mozart (1992), directed by Jean-Pierre Bekolo. The film won prizes at film festivals in Cannes, Locarno, and Montreal and was nominated, in 1993, for a British Film Institute award.McCall eventually applied his mastery of the button to visual art. Since then, he's been proclaimed by American Craft magazine as “The Button Man.” His visual and wearable art has been included in exhibitions at The Museum at FIT, Nordstrom, the African American Museum in Philadelphia, Houston Museum of African American Culture, Charles H. Wright Museum of African American History, Stax Museum of American Soul Music, the Langston Hughes House in partnership with the inaugural Columbia University Wallach Art Gallery Uptown triennial and StoryCorps, and Rush Arts Gallery. McCall's work is held in the permanent collection of public institutions and by private individuals including the Museum of Arts and Design (New York), Philadelphia Museum of Art (Philadelphia), Victoria and Albert Museum (London), The Museum at FIT (New York), Schomburg Center for Research in Black Culture (New York), Amistad Research Center (New Orleans), The Museum of Modern Art Library (New York), Leslie-Lohman Museum of Art (New York), Stonewall National Museum & Archives (Fort Lauderdale), and The San Francisco Museum of Modern Art Library (San Francisco), Cyndi Lauper's True Colors Residence, Debbie Harry of Blondie, Jeffrey Gibson, and Cristina Grajales. McCall has also been commissioned by the Museum of Arts and Design, Columbia University, and the Schomburg Center for Research in Black Culture. And his wearable art can be found in gift shops including the Newark Museum of Art. McCall has been featured in the NY Times, Associated Press, NPR, L.A. Times, and more. In addition, he has served as a teaching artist at the Newark Museum of Art, the New York Public Library, and the Harlem Arts Alliance. McCall has also created a wearable art line called, Triple T-shirts. For these pieces, he upcycles three T-shirts by combining them into one flowing garment that can be worn in six different ways. Each style—from poncho to hoodie to shawl and beyond—brings dynamic versatility to traditional T-shirts. The shirts are curated to form a narrative about various socially-conscious and lighthearted themes.In 2021, McCall released his debut artists' book titled, REWIND: MEMORIES ON REPEAT, commissioned and published by SHINE Portrait Studio@ Express Newark, Rutgers University-Newark. The book honors the legacy of ten of McCall's deceased friends through collages composed of archival photos and images from his button artwork. The collages capture the late 1970s to the mid-1980s, from Philadelphia to New York, during the LGBTQ+ rights movement, the height of disco music and the AIDS crisis.In 2024, McCall debuted his first-ever retrospective and exhibition catalog titled, Beau McCall: Buttons On! at Fuller Craft Museum. The exhibition is currently on a nationwide tour.Through his work, McCall remains committed to channeling and contributing to the universal cultural legacy one button at a time.Visit Beau's Website: BeauMcCall.ComFollow Beau on Instagram: @Beau_McCallFor more on Beau's exhibit "Buttons On!" CLICK HERE--About Podcast Host Emily Wilson:Emily a writer in San Francisco, with work in outlets including Hyperallergic, Artforum, 48 Hills, the Daily Beast, California Magazine, Latino USA, and Women's Media Center. She often writes about the arts. For years, she taught adults getting their high school diplomas at City College of San Francisco.Follow Emily on Instagram: @PureEWilFollow Art Is Awesome on Instagram: @ArtIsAwesome_Podcast--CREDITS:Art Is Awesome is Hosted, Created & Executive Produced by Emily Wilson. Theme Music "Loopster" Courtesy of Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0 LicenseThe Podcast is Co-Produced, Developed & Edited by Charlene Goto of @GoToProductions. For more info, visit Go-ToProductions.com
Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Vidcast: https://www.instagram.com/p/DJ99O5AtU8W/Loss of vision due to retinal degeneration is a devastating complication of diabetes. Now Johns Hopkins research ophthalmologists report in the journal Science Translational Medicine preclinical studies that demonstrate how low blood sugar episodes, known as hypoglycemia, that are experienced by diabetics trigger the development of the blinding retinal damage known as diabetic retinopathy.Studying diabetic mice, the investigators discovered that levels of the protein hypoxia-inducible factor or HIF increase as blood sugar levels decline. HIF, in turn, initiates harmful retinal blood vessel leaks with exposure of retinal cells to toxic circulating elements. This leads to the retinal degeneration characteristic of diabetic retinopathy. Low blood sugar levels fail to induce this toxic chain reaction in non-diabetic mice.The best news is that a drug labeled as 32-134D capably blocks the production of HIF and the increase in retinal blood vessel permeability responsible for diabetic retinopathy. This discovery sets the stage for the development of pharmaceutical agents with similar vision-preserving capabilities.Meanwhile, if you are an insulin-dependent type 1 diabetic of any age, know that stringent control of your blood sugars should emphasize the prevention of hypoglycemic episodes. Speak with your medical team and develop insulin dosing strategies that fulfill this goal. Know how to recognize hypoglycemia and be prepared with foods to counteract it.https://www.science.org/doi/10.1126/scitranslmed.adq5355https://www.sciencedaily.com/releases/2025/05/250506105340.htm#diabetes #hypoglycemia #hif #diabeticretinopathy #32134D
Avsnitt 475 av Sveriges nyfiknaste fotbollspodd gästas av Mattias Lindström. Tränaren talar om att lämna Degerfors efter att ha varit med och tagit upp klubben i allsvenskan, om valet att kliva ner i division 1 igen, om att träna spelare som jobbar vid sidan av fotbollen, om misstagen han gjorde senast på denna nivå, om fotbollen han vill se, om ambitionerna hos Ariana, om växtvärken hos Malmö-klubben och om målet att nå allsvenskan.Dessutom berättar Lindström om valet att satsa på en tränarkarriär, om oron över att poddandet gjort att han inte framstår som seriös, om varför det gick bra i Tvååker, om vad som gick snett i Eskilsminne, om stoltheten över att bli assisterande i Helsingborgs IF, om att det gick för snabbt uppåt för klubben, om de tuffa tagen när han själv var huvudtränare, om vad som gått fel i HIF på senare år och om när klubben kan vara tillbaka i allsvenskan. Hosted on Acast. See acast.com/privacy for more information.
In this JCO PO Article Insights episode, host Harold Tan summarizes Low Kynurenine Levels Among Exceptional Responders on Phase Ib Trial of the HDAC Inhibitor Abexinostat with Pazopanib by Tsang et al, published November 07, 2024. Transcript Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights, where we explore cutting-edge discoveries in the world of cancer treatment and research. I'm Harold Nathan Tan, your host, and today we're taking a focused look at a compelling phase Ib trial led by Dr. Tsang, which investigates a combination of abexinostat, a histone deacetylase inhibitor, with pazopanib, a VEGF-targeting tyrosine kinase inhibitor, in patients with advanced solid tumors. VEGF inhibition has long been an established therapeutic strategy across a wide range of tumor types, including colorectal, ovarian, sarcoma, and renal cell carcinoma. These agents function by disrupting tumor angiogenesis, effectively limiting oxygen and nutrient delivery to malignant cells and contributing to improved survival outcomes. However, over time, acquired resistance remains a significant challenge. A key mechanism implicated in this resistance involves the upregulation of hypoxia-inducible factor 1-alpha, or HIF-1-alpha for short, a master regulator of angiogenesis that restores VEGF signaling under hypoxic conditions. Interestingly, HIF-1-alpha overexpression is mediated by histone deacetylases, especially HDAC2. Preclinical studies suggest that HDAC2 inhibition can suppress tumor cell migration and downregulate HIF-1-alpha activity, effectively disabling a critical escape pathway used by tumors under VEGF pressure. Moreover, combining HDAC inhibition with VEGF blockade has demonstrated synergy in pazopanib-resistant tumor models, forming a compelling rationale for this dual approach. The phase Ib trial by Tsang et al. was designed to evaluate the safety, tolerability, and preliminary efficacy of this dual-targeted approach in patients with heavily pretreated advanced solid tumors. A dose-expansion cohort focused on individuals with renal cell carcinoma, allowing for more detailed evaluation in this population. A central component of this study was the incorporation of biomarker analysis, particularly regarding HDAC2 expression levels. The results were noteworthy. Patients with high HDAC2 expression achieved a progression-free survival of 7.7 months compared to only 3.5 months in those with low expression. Even more compelling, overall survival reached 32.3 months for those with a high HDAC2 expression versus just 9.2 months for those with low expression. This suggests the potential role for HDAC2 as a predictive biomarker for response to combination HDAC and VEGF-targeted therapy. The authors also explored the metabolic landscape of these patients, conducting metabolomic analysis focused on kynurenine, a key tryptophan catabolite known to contribute to the immune suppression in the tumor microenvironment. Its reduction is driven by HIF-1-alpha and inflammatory cytokines, including interleukin-6 and tumor necrosis factor-alpha. What they found was striking. Exceptional responders, defined as patients with treatment responses lasting more than 3 years, had consistently lower levels of kynurenine both before and after treatment. This finding introduces kynurenine as a potential metabolic biomarker. It suggests that patients with lower kynurenine levels may have a less immunosuppressive microenvironment, making them more responsive to the combined effects of HDAC inhibition and VEGF blockade. Of note, VEGF levels themselves did not significantly differ between responders and nonresponders, highlighting that the treatment benefit is not purely VEGF-mediated but likely driven by epigenetic and metabolic modulation. On the safety front, the combination of abexinostat and pazopanib was generally well tolerated. However, this study did report a correlation between higher plasma concentrations of abexinostat and an increased incidence of thrombocytopenia, a class effect associated with HDAC inhibitors. This trial introduces several key considerations for future research. First, it calls for validation of HDAC2 as a predictive biomarker. If confirmed in larger cohorts, HDAC2 expression could be used to select patients most likely to benefit from HDAC inhibitor-based regimens, transforming how we approach trial enrollment and treatment planning. Second, the link between low kynurenine and exceptional response supports further investigation into how metabolic pathways can influence treatment response to combined HDAC and VEGF inhibition. Overall, HDAC inhibitors hold significant promise in precision oncology. Realizing their full therapeutic potential requires a deeper understanding of HDAC biology, refined combination strategies, and thorough preclinical and clinical evaluations tailored to individual patient profiles. This study exemplifies the potential of epigenetic-metabolic crosstalk as a therapeutic vulnerability and underscores the importance of precision stratification in clinical trial design. As research in this space progresses, the integration of molecular, epigenetic, and metabolic profiling will be essential in optimizing the use of HDAC inhibitors and expanding their role within precision oncology. Thank you for tuning into JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. Until then, stay informed and stay inspired. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Avsnitt 470 av Sveriges nyfiknaste fotbollspodd gästas av Jordan Larsson. Anfallaren talar om att jaga nya pokaler med FC Köpenhamn, om krävande supportrar, om att hantera tuff konkurrens, om att för många stjärnor kostade titlar 2024, om att den danska storklubben är ett par steg upp från Malmö FF, om att aktiebolaget FCK satsar rejält och om känslan att FCK kan gå långt i Europa.Dessutom berättar Larsson om valet att satsa på fotbollen framför skolan, om relationen med en del personer i HIF, om Jens Gustafssons betydelse i IFK Norrköping, om den första succén i Spartak Moskva, om reaktionerna när han ensam gick ner på knä för Black Lives Matter, om rysk ilska när han bröt kontraktet efter kriget, om den fina tiden i AIK som fick honom att fundera på att stanna, om besvikelsen när Janne Andersson redan bestämt sig i EM och om hoppet att Jon Dahl Tomasson ska höra av sig. Hosted on Acast. See acast.com/privacy for more information.
The phase 3 LITESPARK-005 trial evaluated patient-reported outcomes (PROs) for belzutifan, a HIF-2α inhibitor, versus everolimus in patients with advanced renal cell carcinoma previously treated with immune checkpoint and anti-angiogenic therapy.
Cristina Suárez analiza los próximos ensayos clínicos que podrían transformar el manejo del cáncer renal en los próximos años: nuevas combinaciones adyuvantes y estrategias perioperatorias, el uso de tripletes enprimera línea y la integración de inhibidores de HIF con TKIs, entre otros.
Featuring perspectives from Dr Thomas E Hutson, Dr Rana R McKay, Dr Sumanta Kumar Pal and Dr Tian Zhang, moderated by Dr Pal, including the following topics: Introduction (0:00) Immunotherapeutic Strategies for Localized and Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Dr Hutson (2:34) Optimal Management of Relapsed/Refractory RCC — Dr Zhang (32:49) Role of HIF-2α Inhibitors in the Treatment of Sporadic and von Hippel-Lindau-Associated RCC — Dr McKay (1:04:02) Current and Future Care of Patients with Non-Clear Cell RCC — Dr Pal (1:33:13) CME information and select publications
Concluding the series on hypoxia inducible factor in skeletal muscle, we go in depth with a paper investigating regulation pathways that blunt HIF's effects in well trained athletes, plus speculate as to whether the Pasteur effect is something worth worrying about while considering other evidence and parallel adaptive pathways. We also ponder some practical takeaways for very well trained endurance athletes as well as for those earlier in their training career.
This week on HIF player we discover how to get around to the things that count with Oliver Burkeman, recorded live at Berwins Salon North. In this uplifting and liberating talk, Oliver Burkeman guides us towards building a more meaningful life in a bewildering era– how to get around to what counts in a world of anxieties and distractions. Addressing the fundamental questions about how to live, Oliver offers a powerful new way to take action: a guiding philosophy of life that he calls ‘imperfectionism'. Oliver's insight will be a source of solace and inspiration, and an aid to a saner, freer, and more enchantment-filled life. Podcast Music by Joseph McDade.
Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
This week on HIF player we learn all about connections with Nick Couldry, recorded live at Berwins Salon North. In this compelling and urgent podcast, Nick Couldry argues that Big Tech is quietly seizing control over our most valuable resource – our personal data. This isn't just about privacy; it's about how your data is being used to shape your behaviour, your choices, and even your future. Nick explains how we ended up here and, more importantly, what we can do about it. Podcast Music by Joseph McDade.
La renuncia el jueves pasado del presidente de Ancap, Alejandro Stipanicic, por diferencias con el Poder Ejecutivo, sigue despertando algunas preguntas. Un breve repaso. Este viernes 27 de diciembre, Alcoholes del Uruguay (ALUR) tiene previsto firmar un Acuerdo de Implementación con la empresa HIF Global. Esto para seguir avanzando con un proyecto de inversión de esa compañía de capitales chilenos en Paysandú, para instalar una planta que utilizará CO2 generado por ALUR e hidrógeno verde para producir combustibles sintéticos. Recordemos que, de concretarse, la planta de HIF supondría la mayor inversión en la historia del país: US$ 6.000 millones. El Acuerdo de Implementación debe firmarse antes de fin de año por una cuestión de plazos estipulados en el memorándum de entendimiento que se firmó con HIF en febrero, pero la decisión final sobre el proyecto se tomaría recién en mayo de 2026. Ahí se espera que el negocio en torno a este proyecto esté más claro, dado que hoy no existe demanda de combustible sintético. ¿Por qué entonces tanta polémica ahora? Entre el presidente saliente del ente, Alejandro Stipanicic, y el Poder Ejecutivo, se abrió una diferencia referente a una cláusula del Acuerdo de Implementación, que le daba a Ancap la opción de participación a futuro en el proyecto. Cuando se tome la decisión final sobre la planta de HIF, Ancap podría tomar una participación hasta del 30% del negocio. Y si allí decidiera no participar, no tendría que pagar ninguna penalización. Stipanicic consideraba que era importante dejar esa opción abierta. Sin embargo, el Poder Ejecutivo exhortó al Directorio de Ancap a eliminar la cláusula en cuestión, y Stipanicic decidió renunciar a su cargo argumentando que no existía “ninguna razón técnica, económica ni jurídica” para seguir el camino ordenado por el gobierno. El sábado, en su cuenta de la red social X, el canciller Omar Paganini, quien fuera previamente ministro de Industria, publicó un texto afirmando que el gobierno pretende que la inversión de HIF siga adelante y la calificó como “una gran oportunidad para el país”. Pero aclaró que Ancap participa como proveedor de CO2 y no como inversor. “El proyecto de HIF no depende de que Ancap invierta. Cuenta con socios de Chile, EEUU, Alemania y Japón. Ellos están asumiendo la inversión y el riesgo, y Ancap obtendrá beneficios rentabilizando un subproducto. Es una situación de ganar-ganar”, escribió Paganini. El jerarca dijo que el monto de la inversión es demasiado alto, y el negocio demasiado incierto, como para que Ancap corra el riesgo. Recordó entonces los casos de Pluna y de la regasificadora, “que costaron muchos millones a los uruguayos”. “Los proyectos de Hidrógeno Verde no deberían ser otra regasificadora”, escribió Paganini. Continuó: “Una cosa es un proyecto con beneficios para Ancap y para los privados, y otra muy diferente es invertir fortunas de los contribuyentes y que por añadidura el Estado salga de garantía”. El canciller cerró diciendo que debe haber una “adecuada asignación de riesgos entre el Estado y los privados” y que “otra cosa son las aventuras con el dinero de todos”. Profundizamos En Perspectiva sore este tema con la actual ministra de Industria, Energía y Minería, la ingeniera Elisa Facio.
Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.
Here we talk with Dr Shai Efrati about HBOT, Hyperbaric Oxygen Therapy and his protocol. It is counterintuitive but the mechanism is through the activation of HIF via hypoxia!
This week on HIF player we explore the most surprising events in recent years with journalist, writer and broadcaster Phoenix Andrews, recorded live at Berwins Salon North. He sheds light on the fascinating world of fandoms and reveals how a passion wave of people power has become the hidden force behind the most surprising events in recent history – from the mass movements resulting in Brexit and Trump, culture wars and conspiracy theories, to online engagement that enriches lives and inspires positive social and political change. Podcast Music by Joseph McDade.
A study knocking out HIF1alpha in mice reveals a counterintuitive relationship between markers of phenotype like fat oxidation, mitochondria markers, capillary density, and fiber type, and not having improved baseline performance. This uncovers an interesting relationship between the HIF pathway and oxidative metabolism, and how seemingly opposing adaptations are complementary.
Sam Jones and Isabel Vieira discuss the 70 year anniversary of private health insurer HIF. Plus, Major MinRes shareholder sells; Perth office vacancies fall; and Orthocell looks to the US market.
References Am J Physiol Cell Physiol 2019 Sep 1;317(3):C502-C512 Browne, J. 2002."Dont You Want to be There?" https://open.spotify.com/track/2e62rpQnEaVoQHWltXWDVV?si=8ba86ab27eeb4972 Simon, P. 1970. "The Boxer" https://open.spotify.com/track/76TZCvJ8GitQ2FA1q5dKu0?si=db43bb95e8504819 Biber, HIF von. 1681. Sonata 8 https://open.spotify.com/track/56hzAmdRl7ndN95YFeksUQ?si=0128734522544c1e --- Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
This week on HIF player we debunk the myths behind running with Allie Bailey, recorded live at Berwins Salon North. Named by The Guardian as “one of the most inspiring female adventurers in the UK”, ultrarunner, adventurer and endurance running and mindset coach Allie Bailey has finished over 200 marathons and ultramarathons and run in some of the most extreme places in the world. The most remarkable thing about all of her achievements, however, is that she accomplished most of them while battling depression and alcoholism.
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros Grivas from Fred Hutchinson Cancer Center and Dr. Sumanta (Monty) Pal from City of Hope. --- CHECK OUT OUR SPONSOR Siemens Healthineers Theranostics https://www.siemens-healthineers.com/en-us/clinical-specialities/theranostics --- SYNPOSIS The conversation initially focuses on advanced urothelial carcinoma and the EV302 trial, discussing detailed insights from the quality-of-life results presented at ASCO. The experts offer relevant clinical perspectives for modern metastatic urothelial carcinoma management, focusing on pembrolizumab plus enfortumab vedotin. Further, they delve into breaking biomarker research at ASCO, including KIM-1 in adjuvant renal cell carcinoma (RCC) therapy and the HIF-2 inhibitor DFF332 for chromophobe RCC. --- TIMESTAMPS 00:00 - Introduction 03:42 - Pembrolizumab and Enfortumab Vedotin Trial Insights 07:43 - Future Trials and Treatment Strategies 21:27 - Javelin Bladder 100 Trial Discussion 32:05 - Growth Factor Use 36:21 - Future Directions of Biomarkers 38:55 - Kidney Cancer Biomarker Trials 53:40 - Concluding Thoughts
Cleaner alternatives to the oil and gas that power vital industries are necessary for economy-wide decarbonization. E-fuels, or electrofuels, are touted as a carbon neutral solution for the hard-to-decarbonize sectors that rely on energy dense fossil fuels. E-fuels are made by combining hydrogen with carbon dioxide. Through the electrolysis process, water is split into oxygen and hydrogen atoms. The hydrogen is then combined with CO2 through a process called synthesis. The outcome is an energy-dense liquid, synthetic fuel. But currently, the e-fuels production process makes these alternatives more expensive than fossil fuels. And when burned, they release CO2, making critics question the claims of climate neutrality. So, what is the climate impact of e-fuels? What industries are turning to these alternatives for decarbonization? And how can policy and tax incentives make them cost competitive with conventional oil and gas? This week host Bill Loveless talks with Meg Gentle about the use of e-fuels for transport. Meg is the executive director of HIF Global, an e-fuel company developing some of the largest projects around the world. Before joining HIF, Meg served as the director of Ovintiv, an independent petroleum company, and as the president and CEO of the natural gas company Tellurian. She also spent ten years working for Cheniere Energy, helping grow their LNG marketing and trading company into a world-wide business.
STARFIGHTER DAN X2M.166 QWAKE הַנְחַת hǎ·neḥǎṯʹ pull back; travel down; penetrate; flatten, sink; deport verb, Hifʿîl, imperative, second person, masculine, singular ± active WAIT-DELIVERANCE PROTOCOL ”May Dan be a snake beside the road, a viper by the path, that bites the heels of the horse so that its rider falls backward. I wait for your deliverance, O Lord.“ Genesis 49:17-18 NET THE DESCENT OF STARFIGHTER ”Let the weak say, ‘I too am a warrior!' Hasten and come, all you surrounding nations, and gather yourselves to that place.” Descend, Yahweh, your champions!“ Joel 3:10-11 FROM THE STATE OF DUST/REST X2M.164 QUIESCENCE TO QWAKE/AWAKENING THE X2M.165 QUASIMODOGENITI ”Will it go down to the barred gates of death? Will we descend together into the dust?”“ Job 17:16 NET DESCENT TO ASCENT: OUT OF EXILE ”Therefore it says, “When he ascended on high he captured captives; he gave gifts to men.” Now what is the meaning of “he ascended,” except that he also descended to the lower regions, namely, the earth? He, the very one who descended, is also the one who ascended above all the heavens, in order to fill all things.“ Ephesians 4:8-10 NET EXIT TO MILLENNIUM ”For the Lord himself will come down from heaven with a shout of command, with the voice of the archangel, and with the trumpet of God, and the dead in Christ will rise first. Then we who are alive, who are left, will be suddenly caught up together with them in the clouds to meet the Lord in the air. And so we will always be with the Lord.” 1 Thessalonians 4:16-17 NET Glorification | The Final Frontier Going Boldly Where The Last Man has Gone Before! Decrease time over target: PayPal or Venmo @clastronaut Cash App $clastronaut
Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ccRCC, and a compelling real-world retrospective study in mUC of patients with FGFR2 and FGFR3 mutations. TRANSCRIPT Dr. Neeraj Agarwal: Hello, everyone, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah's Huntsman Cancer Institute, and editor-in-chief of ASCO Daily News. I am delighted to welcome Dr. Jeanny Aragon-Ching, a genitourinary oncologist and the clinical program director of Genitourinary Cancers at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing key posters and oral abstracts that will be featured at the 2024 ASCO Genitourinary Cancer Symposium, which is celebrating 20 years of evolution in GU oncology this year. You will find our full disclosures in the transcript of this podcast, and disclosures of all guests on the podcast at asco.org/DNpod. Jeanny, it's great to have you on the podcast today to highlight some key abstracts for our listeners ahead of the GU meeting. Dr. Jeanny Aragon-Ching: Thank you so much, Neeraj. It's an honor to be here. Dr. Neeraj Agarwal: Jeanny, as you know, this year we are celebrating the 20th anniversary of the ASCO GU Cancers Symposium, and judging from this year's abstracts, it's clear that this meeting continues to play a major role in advancing GU cancer research. Dr. Jeanny Aragon-Ching: Indeed, Neeraj. This year's abstracts reflect the important strides we have made in GU cancers. So, let's start with the prostate cancer abstracts. What is your takeaway from Abstract 19 on BRCAAway, which will be presented by Dr. Maha Hussein, and of which you are a co-author? As our listeners know, several PARP inhibitor combinations with second-generation androgen receptor pathway inhibitors, or ARPIs, have recently been approved as first-line treatment for patients with metastatic castrate-resistant prostate cancer, or metastatic CRPC, and the question of sequencing PARP inhibitors and ARPIs instead of combining them has emerged. From that perspective, the results of the BRCAAway trial are very important. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: I totally agree with you, Jeanny. The BRCAAway study attempts to answer the crucial questions regarding sequencing versus upfront combination of therapies in the mCRPC setting. It is a phase 2 trial of abiraterone versus olaparib versus abiraterone with olaparib in patients with mCRPC harboring homologous recombination repair mutations. Enrolled patients had mCRPC disease and no prior exposure to PARP inhibitors or ARPIs or chemotherapy in the mCRPC setting and had BRCA1 or BRCA2 or ATM mutations. As previously mentioned, these patients were randomized to 3 arms: abiraterone monotherapy at 1000 milligrams once daily, or olaparib monotherapy at 300 milligrams twice daily, or the combination of abiraterone and olaparib. The primary endpoint was progression-free survival per RECIST 1.1 or Prostate Cancer Working Group 3-based criteria or clinical assessment or death, so, whichever occurred first was deemed to be progression. Secondary endpoints included measurable disease response rates, PSA response rate, and toxicity. This was a relatively small trial with 21 patients in the combination arm, 19 patients in the abiraterone monotherapy arm, and 21 patients in the olaparib monotherapy arm. It should be noted that 26% of patients had received docetaxel chemotherapy in the hormone-sensitive setting, and only 3% of patients had any prior exposure to an ARPI, and these were darolutamide or enzalutamide or in the non-metastatic CRPC setting. The results are very interesting. The median progression-free survival was 39 months in the combination arm, while it was 8.4 months in the abiraterone arm and 14 months in the olaparib arm. An important finding that I would like to highlight is that crossover was also allowed in the monotherapy arms. Of the 19 patients receiving abiraterone, 8 crossed over to receive olaparib, and of the 21 patients receiving olaparib, 8 crossed over to the abiraterone arm. The median PFS from randomization was 16 months in both groups of patients who received abiraterone followed by olaparib or those who received olaparib followed by abiraterone. This is striking when compared to 39 months in patients who started therapy with the combination therapy of abiraterone with olaparib. Dr. Jeanny Aragon-Ching: Thank you so much for that wonderful summary, Neeraj. So the key message from this abstract is that combining olaparib and abiraterone upfront seems to be associated with improvement in PFS compared to just sequencing those agents. Dr. Neeraj Agarwal: Exactly, Jeanny. I would like to add that these results are even more important given that in real-world practice, only half of the patients with mCRPC receive a second-line treatment. Based on these results, upfront intensification with a combination of an ARPI plus a PARP inhibitor in the first-line mCRPC setting seems to have superior efficacy compared to sequencing of these agents. Dr. Jeanny Aragon-Ching: Thank you so much. Now, moving on to a different setting in prostate cancer, there were a couple of abstracts assessing transperineal biopsy compared to the conventional transrectal biopsy for the detection of prostate cancer. So let's start with Abstract 261. Neeraj, can you tell us a little bit more about this abstract? Dr. Neeraj Agarwal: Sure, Jeanny. So, in Abstract 261 titled "Randomized Trial of Transperineal versus Transrectal Prostate Biopsy to Prevent Infection Complications," Dr. Jim Hugh and colleagues led a multicenter randomized trial comparing these 2 approaches, so, transperineal biopsy without antibiotic prophylaxis with transrectal biopsy with targeted prophylaxis in patients with suspected prostate cancer. The primary outcome was post-biopsy infection. Among the 567 participants included in the intention-to-treat analysis, no infection was reported with the transperineal approach, while 4 were detected with the transrectal approach, with a p-value of 0.059. The rates of other complications, such as urinary retention and significant bleeding, were very low and similar in both groups. The investigators also found that detection of clinically significant cancer was similar between the 2 techniques and concluded that the transperineal approach is more likely to reduce the risk of infection without antibiotic prophylaxis. Dr. Jeanny Aragon-Ching: So the key takeaway from this abstract sounds like office-based transperineal biopsy is well-tolerated and does not compromise cancer detection, along with better antibiotic stewardship and health care cost benefits. Moving on to Abstract 273, also comparing these two approaches, what would be your key takeaway message, Neeraj? Dr. Neeraj Agarwal: In this Abstract 273, titled "Difference in High-Risk Prostate Cancer Detection between Transrectal and Transperineal Approaches," Dr. Semko and colleagues found that the transperineal biopsy based on MRI fusion techniques was also characterized by a higher possibility of detecting high-risk prostate cancer and other risk factors as well, such as perineural and lymphovascular invasion or the presence of cribriform pattern, compared to the conventional transrectal method. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So we can see that the transperineal approach is gaining more importance and could be associated with more benefits compared to the conventional methods. Let's now switch gears to kidney cancer, Neeraj. Dr. Neeraj Agarwal: Sure, Jeanny. Let's start by highlighting Abstract 361, which discusses patient-reported outcomes of the LITESPARK-005 study. So what can you tell us about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So as a reminder to our listeners, based on the LITESPARK-005 trial, it was a Phase 3 trial looking at belzutifan, which is an inhibitor of hypoxia inducible factor 2 alpha or I'll just call HIF-2 alpha for short, was very recently approved by the FDA as a second-line treatment option for patients with advanced or metastatic clear cell renal cell carcinoma after prior progression on immune checkpoint and antiangiogenic therapies. The title of Abstract 361 is "Belzutifan versus Everolimus in Patients with Previously Treated Advanced RCC: Patient-Reported Outcomes in the Phase 3 LITESPARK-005 Study," and this will be presented by Dr. Tom Pells at the meeting. At a median follow-up of 25.7 months, the median duration of treatment with belzutifan was 7.6 months, while it was only 3.9 months with everolimus. At the time of data cutoff date for the second interim analysis, 22.6% of patients remained on belzutifan while only 5% remained on everolimus. In the quality of life questionnaires, the time of deterioration to various quality of life scores, as assessed by standardized scales, was significantly longer in patients randomized to the belzutifan arm compared to those in the everolimus arm. Also, patients in the everolimus arm had worse physical functioning scores. Dr. Neeraj Agarwal: Yes, Jeanny. In addition to the improved outcomes associated with belzutifan, patient-reported outcomes indicate better disease-specific symptoms and better quality of life among patients treated with belzutifan compared to everolimus. This is great news for patients with advanced renal cell carcinoma. Now, Jeanny, can you please tell us about the two abstracts that reported longer follow-up of CheckMate 9ER and CheckMate 214 trials in untreated patients with advanced or metastatic renal cell carcinoma? Dr. Jeanny Aragon-Ching: Yes, Neeraj. So you are referring to Abstracts 362 and 363. Let's start with Abstract 362. This abstract reports the results after a median follow-up of 55 months in the CheckMate 9ER trial, comparing the combination of nivolumab and cabozantinib to sunitinib in patients with advanced RCC without any prior treatment, so first-line therapy. The primary endpoint was PFS per RECIST 1.1 as assessed by an independent central review. So there were key secondary outcomes including overall survival (OS), objective response rates, and safety. Consistent with prior analysis at a median follow-up time of 18.1 and 44 months, the combination of nivolumab and cabozantinib at a median follow up of 55.6 months continues to show a significant reduction in the risk of progression or death by 42% and in the risk of death by 23% compared to sunitinib. Dr. Neeraj Agarwal: And Jeanny, what can you tell us about the efficacy results of this combination by IMDC risk categories? Dr. Jeanny Aragon-Ching: Similar to prior results in patients with intermediate to poor risk IMDC risk category, the combination treatment maintained significant efficacy and reduced the risk of progression or death by 44% and the risk of death by 27%. To put it simply, the update now shows a 15-month improvement in overall survival with the cabozantinib-nivolumab combination compared to sunitinib, which is amazing. Also, in patients with favorable IMDC risk group, which represented truly a small number of patients in the trial, there was a strong trend for improvement of outcomes as well. I would like to point out that no new safety concerns were identified. Dr. Neeraj Agarwal: So, it looks like the key message from this abstract is that with longer follow-up, the combination of nivolumab and cabozantinib maintains a meaningful long-term efficacy benefit over sunitinib, supporting its use for newly diagnosed patients with advanced or metastatic renal cell carcinoma. Let's move on to Abstract 363, which compares nivolumab with ipilimumab to sunitinib in first-line advanced renal cell carcinoma. What would you like to tell us about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Yes, Neeraj. The title of this abstract is "Nivolumab plus Ipilimumab versus Sunitinib for the First-Line Treatment of Advanced RCC: Long-Term Follow-Up Data from the Phase 3 CheckMate 214 Trial." In this abstract, Dr. Tannir and colleagues report outcomes with the longest median follow-up in first-line advanced RCC setting for any clinical trial. So the median follow-up now is about 18 months. The primary endpoints were OS, PFS, and objective response rates, as assessed by an independent review according to RECIST 1.1 criteria in the intermediate to poor risk IMDC risk group, which is the intent-to-treat (ITT) analysis, while secondary outcomes included the same outcomes in the ITT population of patients. Although the progression-free survival was similar in both arms, the combination of nivolumab-ipilimumab reduced the risk of death by 28% compared to sunitinib in the ITT population of patients. When stratifying the results by IMDC risk groups, the combination arm of nivolumab-ipilimumab showed significant improvement in the intermediate to poor risk group, but there was no difference in the favorable risk group. But in the study, no new safety signals were identified. Dr. Neeraj Agarwal: Thank you, Jeanny, for such a comprehensive description of the results of these two studies. I'd like to add that the median overall survival of patients with metastatic renal cell carcinoma in the ITT population in the CheckMate 214 trial has now reached 53 months, which would have been unimaginable just a decade ago. This is wonderful news for our patients. So the key takeaway from these two abstracts would be that immune checkpoint inhibitor-based combinations remain the backbone of first-line advanced renal cell carcinoma treatment. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. This is wonderful news for all of our patients, especially for those who are being treated for first-line therapy. Now, let's move on to the bladder cancer abstracts. We have two exciting abstracts from the UNITE database. What are your insights on Abstract 537, titled "Outcomes in Patients with Advanced Urethral Carcinoma Treated with Enfortumab Vedotin After Switch-Maintenance of Avelumab in the UNITE Study"? Dr. Neeraj Agarwal: As our listeners know, enfortumab vedotin is an antibody-drug conjugate that binds to a protein called Nectin 4 expressed on bladder cancer cells. In this abstract, Dr. Amanda Nizam and colleagues describe outcomes in 49 patients receiving third-line enfortumab vedotin after prior progression on platinum-based therapy and maintenance avelumab. At a median follow-up of 8.5 months, the median progression-free survival was 7 months and the median overall survival was 13.3 months with enfortumab vedotin in this treatment-refractory setting, the objective response rates were 54%. The message of this study is that enfortumab vedotin is an effective salvage therapy regimen for those patients who have already progressed on earlier lines of therapies, including platinum-based and immunotherapy regimens. Dr. Jeanny Aragon-Ching: Thank you, Neeraj, for that comprehensive review. I want to focus on another patient population in the UNITE database, which is the use of fibroblast growth factor receptor (FGFR) alterations. Can you tell us more about the sequencing now of erdafitinib and enfortumab vedotin in these patients with metastatic urothelial cancer, as discussed in Abstract 616? Dr. Neeraj Agarwal: Sure, Jeanny. As a reminder, erdafitinib is a fibroblast growth factor receptor kinase inhibitor approved for patients with locally advanced or metastatic urothelial carcinoma harboring FGFR2 or FGFR3 alterations after progression on platinum-based chemotherapy. However, the optimal sequencing of therapies in these patients is unclear, especially with enfortumab vedotin being approved in the salvage therapy setting and now in the frontline therapy setting. So in this retrospective study, all patients with metastatic urothelial carcinoma had FGFR2 or FGFR3 alterations. Dr. Cindy Jiang and colleagues report outcomes in 24 patients receiving enfortumab vedotin after erdafitinib, 15 patients receiving erdafitinib after enfortumab vedotin, and 55 patients receiving enfortumab vedotin only. This is a multicenter national study. Interestingly, patients receiving both agents had a longer overall survival in a multivariate analysis, regardless of the treatment sequencing, than patients receiving enfortumab vedotin alone or only with a hazard ratio of 0.52. The objective response rate of enfortumab vedotin in the enfortumab vedotin monotherapy arm was 49%. When these agents were sequenced, the objective response with enfortumab vedotin was 32% after erdafitinib and 67% when used before erdafitinib. Dr. Jeanny Aragon-Ching: Thank you so much, Neeraj. I think these are important real-world data results, but I would like to point out that larger and prospective studies are still needed to confirm these findings, especially regarding the outcome of erdafitinib after enfortumab vedotin, particularly when the latter is used in the first-line setting. Dr. Neeraj Agarwal: I totally agree, Jeanny. Now, let's discuss some abstracts related to disparities in the management of patients with genitourinary cancers. Dr. Jeanny Aragon-Ching: Sure, actually, I would like to discuss 2 abstracts related to disparities in patients with prostate cancer. So the first one, Abstract 265, titled "Patient-Provider Rurality and Outcomes in Older Men with Prostate Cancer." In this study, Dr. Stabellini, Dr. Guha and the team used a SEER Medicare-linked database that included more than 75,000 patients with prostate cancer. The primary outcome was all-cause mortality, with secondary outcomes included prostate cancer-specific mortality. The investigators showed that the all-cause mortality risk was 44% higher in patients with prostate cancer from rural areas who had a provider from a non-metropolitan area compared to those who were in a metropolitan area and had a provider also from a metropolitan area. Dr. Neeraj Agarwal: Those are very important data and highlight the healthcare disparities among the rural population with prostate cancer that still exist. So what is your key takeaway from Abstract 267, titled "Rural-Urban Disparities in Prostate Cancer Survival," which is a population-based study? Dr. Jeanny Aragon-Ching: Of course. This abstract discusses, actually, a very similar issue regarding access to healthcare among rural versus urban patients. In this study, Dr. Hu and Hashibe and colleagues and team at the Huntsman Cancer Institute assessed all-cause death and prostate cancer-related death risk in a retrospective study in which patients with prostate cancer based on rural versus urban residencies looked at 18,000 patients diagnosed with prostate cancer between 2004 and 2017. 15% lived in rural counties. Similar to the prior abstract we talked about, patients living in rural areas had about a 19% higher risk of all-cause mortality and a 21% higher risk of prostate cancer-specific mortality in comparison to patients living in urban areas. Dr. Neeraj Agarwal: So Jeanny, we can say that both of these abstracts, led by different groups of investigators, highlight that patients with prostate cancer living in rural areas have inferior survival outcomes compared to those living in urban areas, and it is time to focus on the disparities experienced by the rural population with prostate cancer. Dr. Jeanny Aragon-Ching: Yeah, absolutely Neeraj. I concur with your thoughts. So, any final thoughts before we wrap up the podcast today? Dr. Neeraj Agarwal: Yes, before concluding, Jeanny, I want to express my gratitude for your participation and the valuable insights you have shared today. Your contributions are always appreciated, and I sincerely thank you for taking the time to join us today. As we bring this podcast to a close, I would like to highlight the significant advances happening in the treatment of patients with genitourinary cancers during our upcoming 2024 ASCO GU meeting. Many studies featuring practice-impacting data will be presented by investigators from around the globe. I encourage our listeners to not only participate at this event to celebrate these achievements, but to also play a role in disseminating these cutting-edge findings to practitioners worldwide. By doing so, we can collectively maximize the benefit for patients around the world. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Thank you very much. Disclaimer: The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guest speakers express their own opinions, experience, and conclusions. Guest statements on the podcast do not necessarily reflect the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics.
Have you considered oxygen as being part of YOUR solution for fixing leaky gut? Intestinal permeability (leaky gut) is a major issue, driving up inflammation in the body. Leaky gut is also at the root of autoimmune conditions (eczema, cirrhosis, lupus, and rheumatoid arthritis – to name a few). It is something that the wellness world is trying to solve from several approaches. Today's guest is one such member of the natural health and wellness world: health engineer and gut health specialist Steven Wright. Steven has created a wide range of products to keep your gut healthy, all of which can be found on his website, healthygut.com. Steven has been doing some amazing research on delivering oxygen to our guts to strengthen our intestinal lining and heal up some of the 'tight junctions' that develop over time. He is at the cutting edge of gut health research and his approach to how we consider the entire environment of our gut is one that will resonate with fans of Dr. Jockers and his holistic approach to health. This episode is an absolute must-listen for anyone dealing with chronic auto-immune conditions. So please take the time to share it with them; you never know when you may save or improve someone's life with a new approach to a health problem they may be struggling with. This is valuable information that can give you a 'leg up' on your wellness journey. Please join us and leave us a five-star review along the way! In This Episode: Introduction to Steven Wright What are some of the biggest mistakes people are making in terms of treating leaky gut? Why we shouldn't only focus on 'tight junction integrity' Understanding immune dysfunction What happens when expensive supplements don't work? Appreciating that different tissues have different needs Why is oxygen so important? What are HIFs? Is there a way to test your HIF levels? What are some strategies to improve your gut's microbiome diversity? What happens when you replace Butyric Acid as a supplement? Where do stomach acids and enzymes fit in the hierarchy of gut support? How probiotics help with immune system regulation When do you introduce probiotics? What does apple cider vinegar do? When to go in the opposite direction to find your gut solution Unpacking the role of glyphosate (herbicide) on leaky gut syndrome Addressing our overall toxic environment What is the key to getting Butyric Acid deep into our system? What kind of results is Steven Wright getting with Tributyrin-X? The importance of low oxygen environment in our gut "Just keep going!" - final words of inspiration This podcast is sponsored by ShopC60.com. C60 is a powerful, Nobel Prize-winning antioxidant, that helps to optimize mitochondrial function, fights inflammation, and neutralizes toxic free radicals! I'm a big fan of using C60 in conjunction with your keto and intermittent fasting lifestyle to support your immune system, help your body detox, and increase energy and mental clarity. My favorite C60 products for Keto & IF lifestyles include C60 Purple Power in Organic MCT Coconut Oil (can add this to your coffee) and their delicious Sugar-Free C60 Gummies (made with allulose and monk fruit)! If you are over the age of 40, and you'd like to kick fatigue and brain fog to the curb this year, visit shopc60.com and use the coupon code “JOCKERS” for 15% OFF and start taking back control over your health today! When it comes to gut health, bone broth is one of my ‘go to' items I add to my diet. But, not all collagen is created equal. Many brands use poor-quality bones and heating methods that remove all of the potent benefits of collagen. That is why I choose to use Paleovalley Bone Broth Protein Powder, you can get all the gut healing benefits without the mess from a company that uses only 100% grass-fed and finished cows and is not processed with high heat or extracted with harmful chemicals. There are no fillers, flow agents, or added flavors. There is only ONE ingredient in this product and it's bovine bone broth protein. Hurry and grab yours from Paleovalley.com “If you don't have the right environment for the gut to behave, you can't expect it to behave correctly" - Steven Wright Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean TuneIn Radio Resources: Shop Carbon 60 - Use the coupon code "JOCKERS" for 15% OFF your first order in all their products! paleovalley.com/jockers Connect with Steven Wright: Website - https://healthygut.com/ Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https://www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/
In this episode we discuss: Why uncoupling is harmful in certain contexts and how PUFA cause constant, low-level uncoupling The involvement of uncoupling, mitochondrial biogenesis, autophagy, heat shock proteins, and hypoxia-inducible factors in the stress response How stress prevents our mitochondria from effectively producing energy How chronic stress causes insulin resistance, high blood pressure, weight gain, depression, and cardiovascular disease How sugar and fat cravings result from stress and why listening to them is beneficial How adaptations to stress get passed on through generations Sign up for the Free Energy Balance Mini-Course here: https://jayfeldmanwellness.com/energy Click here to check out the show notes: https://www.jayfeldmanwellness.com/ep-94-how-stress-crashes-your-metabolism-why-hormesis-is-not-the-answer-stress-mitochondria-part-2/ Timestamps: 0:00 – intro 2:59 – the details of how mitochondrial respiration can become disrupted, especially from glucocorticoids 6:05 – the short-term effects of catecholamines 8:34 – why uncoupling is harmful in certain contexts and how PUFA cause constant, low-level uncoupling 14:40 – the protective effects of uncoupling as a part of the stress response 20:08 – the role of cytokines (TNF-alpha, IL-1, IL-6, heat-shock proteins, NF-kB, HIF) in the stress response 37:33 – the effect of acute stress on energy production in mitochondria 45:18– the effect of chronic stress on energy production in mitochondria 48:15 – how stress drives degeneration and the evidence for increased activity of hormetic pathways (including effects like mitochondrial biogenesis and autophagy) in degenerative states 1:05:24 – the relationship between mental health, mood, and metabolic function 1:10:21 – how adaptations to stress get passed on through mitochondrial DNA 1:18:32 – how to best improve mitochondrial function and our health
© 2020-2026 Ivy Podcast Discovery LLC
